Therefore, given the rapid and significant increase in urinary volume excretion under empagliflozin, we hypothesize that SGLT2 inhibitors could be a promising new treatment option for patients with SIADH. The gene discussed is SLC5A2; the disease is inappropriate ADH syndrome.